A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a progressive, fatal disease with no known efficacious therapy. METHODS: In a double-blind, multinational trial, we randomly assigned 330 patients with idiopathic pulmonary fibrosis that was unresponsive to corticosteroid therapy to receive subcutaneous interferon gamma-1b or placebo. RESULTS: Over a median of 58 weeks, interferon gamma-1b therapy did not significantly affect the primary end point of progression-free survival, defined as the time to disease progression or death, and no significant treatment effect was observed on measures of lung function, gas exchange, or the quality of life. Ten percent of patients in the interferon gamma-1b group died, as compared with 17 percent of patients in the placebo group (P=0.08). Treatment with interferon gamma-1b was associated with more frequent constitutional symptoms. However, the rates of treatment adherence and premature discontinuation of treatment were similar in the two groups. More pneumonias were reported among patients in the interferon gamma-1b group, but the incidence of severe or life-threatening respiratory tract infections was similar in the two groups. CONCLUSIONS: In a well-defined population of patients with idiopathic pulmonary fibrosis, interferon gamma-1b did not affect progression-free survival, pulmonary function, or the quality of life. Owing to the size and duration of the trial, a clinically significant survival benefit could not be ruled out.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, systemic administration of recombinant IFNγ (which would simulate the presence of Th1 biology) and monoclonal antibody-mediated neutralization of IL-13 (which would specifically target Th2 responses) failed to demonstrate efficacy in randomized, placebo-controlled trials of patients with IPF (141, 142).”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [141]
Citations
Cites
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Nathan, C. F., Murray, H. W., Wiebe, M. E., & Rubin, B. Y. (1983) · The Journal of experimental medicine · doi:10.1084/jem.158.3.670 · Cited by 1,962
Mahler, D. A., Weinberg, D. H., Wells, C. K., & Feinstein, A. R. (1984) · Chest · doi:10.1378/chest.85.6.751 · Cited by 1,292
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039
Editorial: Cerebral Palsy—the International Consensus Statement
Clements, R. V., & Simanowitz, A. (2000) · Clinical Risk · doi:10.1177/135626220000600401 · Cited by 856
Predicting Survival in Idiopathic Pulmonary Fibrosis
KING, T. E., TOOZE, J. A., SCHWARZ, M. I., BROWN, K. R., & CHERNIACK, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.7.2003140 · Cited by 853
Self-citationinternational consensus statement
Clements, R. V., & Simanowitz, A. (2000) · Cited by 852
Gajewski, T. F., & Fitch, F. W. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.12.4245 · Cited by 834
Broekelmann, T. J., Limper, A. H., Colby, T. V., & McDonald, J. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.15.6642 · Cited by 794
Ziesche, R., Hofbauer, E., Wittmann, K., Petkov, V., & Block, L.-H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910213411703 · Cited by 586
Raghu, G., Depaso, W. J., Cain, K., Hammar, S. P., Wetzel, C. E., Dreis, D. F., Hutchinson, J., Pardee, N. E., & Winterbauer, R. H. (1991) · American Review of Respiratory Disease · doi:10.1164/ajrccm/144.2.291 · Cited by 414
Self-citationThe CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis
Keane, M. P., Arenberg, D. A., Lynch, J. P., Whyte, R. I., Iannettoni, M. D., Burdick, M. D., Wilke, C. A., Morris, S. B., Glass, M. C., DiGiovine, B., et al. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.3.1437 · Cited by 382
Determinants of survival in idiopathic pulmonary fibrosis.
Schwartz, D. A., Helmers, R. A., Galvin, J. R., Van Fossen, D. S., Frees, K. L., Dayton, C. S., Burmeister, L. F., & Hunninghake, G. W. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.149.2.8306044 · Cited by 340
Self-citationBuerger, H., Otterbach, F., Simon, R., Poremba, C., Diallo, R., Decker, T., Riethdorf, L., Brinkschmidt, C., Dockhorn-Dworniczak, B., & Boecker, W. (1999) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199903)187:4<396::aid-path286>3.0.co;2-l · Cited by 328
Assessment of Health-Related Quality of Life in Patients With Interstitial Lung Disease
Chang, J. A., Curtis, J. R., Patrick, D. L., & Raghu, G. (1999) · Chest · doi:10.1378/chest.116.5.1175 · Cited by 302
Self-citationJohnson, M. A., Kwan, S., Snell, N. J., Nunn, A. J., Darbyshire, J. H., & Turner-Warwick, M. (1989) · Thorax · doi:10.1136/thx.44.4.280 · Cited by 289
Pulmonary fibrosis: cytokines in the balance
Coker, R., & Laurent, G. (1998) · European Respiratory Journal · doi:10.1183/09031936.98.11061218 · Cited by 267
DOUGLAS, W. W., RYU, J. H., & SCHROEDER, D. R. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.4.9907002 · Cited by 259
Expression of β‐defensin 1 and 2 mRNA by human monocytes, macrophages and dendritic cells
Duits, L. A., Ravensbergen, B., Rademaker, M., Hiemstra, P. S., & Nibbering, P. H. (2002) · Immunology · doi:10.1046/j.1365-2567.2002.01430.x · Cited by 249
Flaherty, K. R., Toews, G. B., Lynch, J. P., Kazerooni, E. A., Gross, B. H., Strawderman, R. L., Hariharan, K., Flint, A., & Martinez, F. J. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00711-7 · Cited by 184
Cytokine reference : a compendium of cytokines and other mediators of host defence
Durum, S. K., Oppenheim, J. J., Feldmann, M., Hirano, T., Vilec, J., & Nicola, N. A. (2001) · Academic Press eBooks · Cited by 145
Colchicine, D-Penicillamine, and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis
Selman, M., Carrillo, G., Salas, J., Pérez‐Padilla, R., Pèrez-Chavira, R., Sansores, R., & Chapela, R. (1998) · CHEST Journal · doi:10.1378/chest.114.2.507 · Cited by 128 · cited 1×
“Influenza-like illness 31 (19) 13 (8) 0.”
In vivo levels and in vitro production of interferon-gamma in fibrosing interstitial lung diseases
PRIOR, C., & HASLAM, P. L. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1992.tb03074.x · Cited by 118 · cited 1×
“Nausea, vomiting, or both†† 29 (18) 49 (29) 0.”
Sáez-Royuela, F., Porres, J. C., Moreno, A., Castillo, I., Martinez, G., Galiana, F., & Carreño, V. (1991) · Hepatology · doi:10.1016/0270-9139(91)92448-h · Cited by 116
Recombinant interferon-γ in the treatment of systemic sclerosis
Kahan, A., Amor, B., Menkes, C. J., & Strauch, G. (1989) · The American Journal of Medicine · doi:10.1016/s0002-9343(89)80150-0 · Cited by 104
Sáez-Royuela, F., Porres, J. C., Moreno, A., Castillo, I., Martınez, G., Galiana, F., & Carréño, V. (1991) · Hepatology · doi:10.1002/hep.1840130220 · Cited by 104
Effect of γ-Interferon on Collagen Synthesis by Normal and Fibrotic Human Lung Fibroblasts
Narayanan, A. S., Whithey, J., Souza, A. E., & Raghu, G. (1992) · CHEST Journal · doi:10.1378/chest.101.5.1326 · Cited by 101
Self-citationClark, J. G., Dedon, T. F., Wayner, E. A., & Carter, W. G. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114045 · Cited by 79
Treatment of systemic sclerosis with γ-interferon
Hein, R., Behr, J., Hündgen, M., Hunzelmann, N., Meurer, M., Braun‐Falco, O., Urbanski, A., & Krieg, T. M. (1992) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1992.tb11824.x · Cited by 79
Wallace, W. A., & Howie, S. (1999) · The Journal of Pathology · Cited by 79
Distinct functions of interferon‐γ for chemokine expression in models of acute lung inflammation
NEUMANN, EMMANUILIDIS, Stadler, & HOLZMANN (1998) · Immunology · doi:10.1046/j.1365-2567.1998.00643.x · Cited by 50
Okada, T., Sugie, I., & Aisaka, K. (1993) · PubMed · Cited by 46
Determinants of response to immunosuppressive therapy in idiopathic pulmonary fibrosis
Oortegem, K. V., Wallaert, B., Marquette, C., Ramon, P.-P., Perez, T., Lafitte, J., & Tonnel, A. (1994) · European Respiratory Journal · doi:10.1183/09031936.94.07111950 · Cited by 44
Kuroki, S., OHTA, A., Sueoka, N., Katoh, O., Yamada, H., & Yamaguchi, M. (1995) · Rheumatology · doi:10.1093/rheumatology/34.1.31 · Cited by 32
The Role of Nebulized IFN-γ in the Modulation of Allergic Responses
Lack, G., & Gelfand, E. W. (1996) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-5855-2_3 · Cited by 5
Research works printed but not linked: 2
- Okada T, 1993, Lymphokine Cytokine Res, 12, 87
- 10.1002/(sici)1096-9896(199903)187:4<475::aid-path268>3.0.co;2-n · doi:10.1002/(sici)1096-9896(199903)187:4<475::aid-path268>3.0.co;2-n
Cited by
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationKing, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationProtein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationClinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Self-citation
Metadata
- Authors
- Raghu, G., Brown, K. K., Bradford, W. Z., Starko, K., Noble, P. W., Schwartz, D. A., & King, T. E.
- Affiliations
- University of Washington (US)
- National Jewish Health (US)
- Yale University (US)
- Duke University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-01-08
- Volume
- 350
- Issue
- 2
- Pages
- 125-133
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2108226118
- Cited by
- 652
- References
- 34
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 8 · 2023: 15 · 2022: 15 · 2021: 16 · 2020: 15 · 2019: 17 · 2018: 11 · 2017: 22 · 2016: 21 · 2015: 29 · 2014: 20 · 2013: 38 · 2012: 39
- FWCI
- 54.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- idiopathic pulmonary fibrosis, interferon gamma-1b, progression-free survival, corticosteroid-refractory disease, lung function, quality of life, mortality, pneumonia, constitutional symptoms, medication adherence
- MeSH terms
- Double-Blind Method, Female, Humans, Injections, Subcutaneous, Interferon-gamma, Male, Middle Aged, Pulmonary Fibrosis, Recombinant Proteins, Respiratory Function Tests, Respiratory Tract Infections, Risk, Proportional Hazards Models, Treatment Failure, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.